Equities analysts forecast that Humana Inc. (NYSE:HUM) will post $13.29 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Humana’s earnings, with the highest sales estimate coming in at $13.49 billion and the lowest estimate coming in at $13.11 billion. Humana reported sales of $13.69 billion during the same quarter last year, which would suggest a negative year over year growth rate of 2.9%. The business is expected to issue its next quarterly earnings results before the market opens on Wednesday, November 8th.
On average, analysts expect that Humana will report full year sales of $13.29 billion for the current fiscal year, with estimates ranging from $52.60 billion to $54.10 billion. For the next year, analysts anticipate that the business will report sales of $56.58 billion per share, with estimates ranging from $54.59 billion to $58.34 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Humana.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The company had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the previous year, the firm posted $2.30 EPS.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Tuesday. BMO Capital Markets assumed coverage on shares of Humana in a report on Monday. They set an “outperform” rating and a $300.00 target price on the stock. Jefferies Group LLC reissued a “hold” rating and set a $257.00 target price on shares of Humana in a report on Friday, October 13th. Royal Bank Of Canada reissued a “hold” rating and set a $245.00 target price on shares of Humana in a report on Tuesday, October 10th. Finally, ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Twelve investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $253.90.
In other Humana news, VP M Todoroff Christopher sold 22,935 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the completion of the sale, the vice president now directly owns 24,001 shares in the company, valued at $6,060,732.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider William Kevin Fleming sold 3,071 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The disclosure for this sale can be found here. Insiders sold 55,595 shares of company stock valued at $14,133,706 over the last quarter. 0.80% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC boosted its position in Humana by 31.6% during the second quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock valued at $151,792,000 after buying an additional 151,603 shares during the period. Prisma Capital Partners LP purchased a new stake in Humana during the second quarter valued at about $7,122,000. Koch Industries Inc. purchased a new stake in Humana during the second quarter valued at about $404,000. Federated Investors Inc. PA boosted its position in Humana by 608.1% during the second quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock valued at $8,331,000 after buying an additional 29,736 shares during the period. Finally, Commonwealth Bank of Australia boosted its position in Humana by 4.0% during the second quarter. Commonwealth Bank of Australia now owns 20,316 shares of the insurance provider’s stock valued at $4,887,000 after buying an additional 775 shares during the period. Institutional investors and hedge funds own 95.11% of the company’s stock.
Shares of Humana (NYSE HUM) traded up 1.29% during mid-day trading on Tuesday, reaching $245.81. 742,585 shares of the company’s stock were exchanged. The stock has a market capitalization of $35.52 billion, a PE ratio of 20.22 and a beta of 0.86. The company’s 50 day moving average is $245.96 and its 200 day moving average is $236.38. Humana has a 1-year low of $165.03 and a 1-year high of $259.76.
The business also recently announced a dividend, which was paid on Monday, October 16th. Investors of record on Friday, September 29th were given a $0.40 dividend. The ex-dividend date was Thursday, September 28th. Humana’s dividend payout ratio (DPR) is presently 13.06%.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.